Concepts (261)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urethral Stricture | 57 | 2025 | 69 | 18.160 |
Why?
|
| Urethra | 45 | 2025 | 75 | 9.380 |
Why?
|
| Urologic Surgical Procedures, Male | 37 | 2025 | 52 | 6.020 |
Why?
|
| Lichen Sclerosus et Atrophicus | 10 | 2025 | 20 | 4.850 |
Why?
|
| Mouth Mucosa | 11 | 2025 | 24 | 4.020 |
Why?
|
| Urinary Fistula | 8 | 2022 | 17 | 2.940 |
Why?
|
| Surgical Flaps | 10 | 2023 | 116 | 2.420 |
Why?
|
| Urethral Diseases | 8 | 2022 | 13 | 2.190 |
Why?
|
| Rectal Fistula | 5 | 2022 | 21 | 2.120 |
Why?
|
| Retrospective Studies | 53 | 2025 | 6643 | 1.810 |
Why?
|
| Postoperative Complications | 18 | 2024 | 1290 | 1.800 |
Why?
|
| Radiation Injuries | 5 | 2021 | 67 | 1.550 |
Why?
|
| Prostatic Neoplasms | 9 | 2022 | 418 | 1.500 |
Why?
|
| Male | 77 | 2025 | 29956 | 1.440 |
Why?
|
| Endoscopy | 6 | 2021 | 112 | 1.250 |
Why?
|
| Urinary Bladder Neck Obstruction | 4 | 2020 | 6 | 1.220 |
Why?
|
| Intestinal Mucosa | 4 | 2021 | 242 | 1.220 |
Why?
|
| Middle Aged | 51 | 2025 | 17677 | 1.200 |
Why?
|
| Humans | 96 | 2025 | 63573 | 1.180 |
Why?
|
| Gracilis Muscle | 2 | 2020 | 3 | 1.160 |
Why?
|
| Pubic Symphysis | 2 | 2019 | 4 | 1.130 |
Why?
|
| Conservative Treatment | 2 | 2025 | 17 | 1.090 |
Why?
|
| Cystoscopy | 7 | 2020 | 17 | 1.060 |
Why?
|
| Constriction, Pathologic | 7 | 2023 | 128 | 1.040 |
Why?
|
| Urinary Incontinence | 4 | 2024 | 44 | 1.030 |
Why?
|
| Urethral Neoplasms | 2 | 2016 | 3 | 0.960 |
Why?
|
| Pelvic Bones | 6 | 2022 | 17 | 0.960 |
Why?
|
| Adult | 45 | 2025 | 16899 | 0.950 |
Why?
|
| Robotics | 3 | 2019 | 86 | 0.940 |
Why?
|
| Hematuria | 2 | 2024 | 21 | 0.940 |
Why?
|
| Aged | 38 | 2025 | 14477 | 0.920 |
Why?
|
| Rivaroxaban | 1 | 2024 | 19 | 0.890 |
Why?
|
| Recurrence | 14 | 2024 | 642 | 0.850 |
Why?
|
| Treatment Outcome | 23 | 2025 | 5668 | 0.850 |
Why?
|
| Follow-Up Studies | 16 | 2025 | 2464 | 0.820 |
Why?
|
| Urinary Bladder | 3 | 2018 | 44 | 0.800 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2023 | 7 | 0.790 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2024 | 228 | 0.770 |
Why?
|
| Urologic Surgical Procedures | 9 | 2022 | 44 | 0.750 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2019 | 31 | 0.740 |
Why?
|
| Urinary Retention | 1 | 2022 | 29 | 0.720 |
Why?
|
| Wounds and Injuries | 2 | 2016 | 248 | 0.710 |
Why?
|
| Fractures, Bone | 5 | 2022 | 143 | 0.700 |
Why?
|
| Aged, 80 and over | 14 | 2021 | 5481 | 0.700 |
Why?
|
| Ejaculation | 2 | 2021 | 8 | 0.690 |
Why?
|
| Urology | 5 | 2025 | 44 | 0.680 |
Why?
|
| Surgeons | 1 | 2023 | 184 | 0.670 |
Why?
|
| Anticoagulants | 1 | 2024 | 495 | 0.660 |
Why?
|
| Urinary Bladder, Neurogenic | 2 | 2010 | 7 | 0.650 |
Why?
|
| Patient Reported Outcome Measures | 5 | 2025 | 156 | 0.650 |
Why?
|
| Urinary Sphincter, Artificial | 4 | 2025 | 6 | 0.630 |
Why?
|
| Lasers, Solid-State | 1 | 2019 | 18 | 0.630 |
Why?
|
| Osteomyelitis | 1 | 2019 | 25 | 0.620 |
Why?
|
| Penile Diseases | 3 | 2025 | 7 | 0.610 |
Why?
|
| Natural Orifice Endoscopic Surgery | 2 | 2017 | 41 | 0.590 |
Why?
|
| Contracture | 1 | 2017 | 9 | 0.550 |
Why?
|
| Reoperation | 6 | 2021 | 290 | 0.540 |
Why?
|
| Mitomycin | 2 | 2020 | 26 | 0.520 |
Why?
|
| Urogenital System | 1 | 2016 | 3 | 0.500 |
Why?
|
| Urinary Incontinence, Urge | 4 | 2022 | 4 | 0.500 |
Why?
|
| Urologic Diseases | 1 | 2016 | 17 | 0.500 |
Why?
|
| Rectus Abdominis | 1 | 2016 | 3 | 0.490 |
Why?
|
| Prostatic Diseases | 1 | 2016 | 9 | 0.490 |
Why?
|
| Fistula | 1 | 2016 | 14 | 0.490 |
Why?
|
| Iatrogenic Disease | 1 | 2016 | 62 | 0.490 |
Why?
|
| Joint Diseases | 1 | 2016 | 20 | 0.480 |
Why?
|
| Microsurgery | 1 | 2016 | 53 | 0.480 |
Why?
|
| MicroRNAs | 1 | 2021 | 691 | 0.460 |
Why?
|
| Cystostomy | 3 | 2022 | 3 | 0.450 |
Why?
|
| Disease Management | 1 | 2016 | 233 | 0.450 |
Why?
|
| Anastomosis, Surgical | 6 | 2021 | 116 | 0.450 |
Why?
|
| Chemoradiotherapy | 1 | 2014 | 69 | 0.430 |
Why?
|
| Penis | 4 | 2023 | 34 | 0.420 |
Why?
|
| Quality of Life | 6 | 2025 | 1241 | 0.410 |
Why?
|
| Algorithms | 1 | 2018 | 1004 | 0.410 |
Why?
|
| Rectum | 3 | 2019 | 91 | 0.400 |
Why?
|
| Urethral Obstruction | 2 | 2022 | 6 | 0.390 |
Why?
|
| Time Factors | 6 | 2025 | 3731 | 0.390 |
Why?
|
| Scrotum | 3 | 2023 | 8 | 0.380 |
Why?
|
| Cohort Studies | 9 | 2024 | 2575 | 0.370 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 259 | 0.370 |
Why?
|
| Trauma Centers | 2 | 2012 | 125 | 0.360 |
Why?
|
| Urinary Tract Infections | 3 | 2022 | 92 | 0.360 |
Why?
|
| Preoperative Period | 3 | 2020 | 69 | 0.360 |
Why?
|
| Nephrectomy | 1 | 2012 | 91 | 0.350 |
Why?
|
| Risk Factors | 9 | 2024 | 5316 | 0.350 |
Why?
|
| Minimally Invasive Surgical Procedures | 5 | 2019 | 129 | 0.340 |
Why?
|
| Urinary Incontinence, Stress | 2 | 2022 | 25 | 0.340 |
Why?
|
| Biomarkers | 3 | 2023 | 1407 | 0.340 |
Why?
|
| Ileostomy | 1 | 2010 | 27 | 0.340 |
Why?
|
| Patient Satisfaction | 3 | 2019 | 436 | 0.330 |
Why?
|
| Prostatectomy | 5 | 2024 | 99 | 0.320 |
Why?
|
| Penile Induration | 1 | 2009 | 2 | 0.320 |
Why?
|
| Young Adult | 8 | 2020 | 4716 | 0.320 |
Why?
|
| Dilatation | 2 | 2021 | 31 | 0.310 |
Why?
|
| Ileum | 1 | 2009 | 21 | 0.310 |
Why?
|
| Severity of Illness Index | 7 | 2024 | 1556 | 0.310 |
Why?
|
| Kidney | 1 | 2012 | 448 | 0.310 |
Why?
|
| Female | 12 | 2024 | 32971 | 0.300 |
Why?
|
| Cystectomy | 3 | 2019 | 35 | 0.300 |
Why?
|
| Urinary Diversion | 3 | 2017 | 12 | 0.300 |
Why?
|
| Urography | 2 | 2020 | 13 | 0.290 |
Why?
|
| Prospective Studies | 9 | 2024 | 3302 | 0.290 |
Why?
|
| Risk Assessment | 6 | 2024 | 2045 | 0.290 |
Why?
|
| Urogenital Neoplasms | 1 | 2008 | 5 | 0.280 |
Why?
|
| Urination | 4 | 2022 | 13 | 0.280 |
Why?
|
| Radiotherapy | 2 | 2020 | 63 | 0.280 |
Why?
|
| Lymph Node Excision | 1 | 2008 | 46 | 0.280 |
Why?
|
| Combined Modality Therapy | 4 | 2020 | 375 | 0.270 |
Why?
|
| Sexual Behavior | 2 | 2019 | 194 | 0.270 |
Why?
|
| Perineum | 2 | 2025 | 19 | 0.270 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 770 | 0.260 |
Why?
|
| Laparoscopy | 2 | 2010 | 494 | 0.260 |
Why?
|
| Robotic Surgical Procedures | 2 | 2021 | 160 | 0.260 |
Why?
|
| Inflammation | 2 | 2024 | 1147 | 0.250 |
Why?
|
| Urodynamics | 3 | 2018 | 12 | 0.240 |
Why?
|
| Models, Anatomic | 1 | 2025 | 64 | 0.230 |
Why?
|
| Enoxaparin | 1 | 2024 | 17 | 0.220 |
Why?
|
| Treatment Failure | 1 | 2025 | 201 | 0.220 |
Why?
|
| Simulation Training | 1 | 2025 | 64 | 0.220 |
Why?
|
| Cystitis | 1 | 2023 | 10 | 0.210 |
Why?
|
| Fibrosis | 1 | 2024 | 160 | 0.210 |
Why?
|
| Causality | 1 | 2023 | 58 | 0.210 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2023 | 16 | 0.200 |
Why?
|
| Learning Curve | 2 | 2015 | 35 | 0.200 |
Why?
|
| Incidence | 2 | 2024 | 1380 | 0.200 |
Why?
|
| Immunohistochemistry | 4 | 2019 | 895 | 0.190 |
Why?
|
| Surveys and Questionnaires | 4 | 2018 | 2703 | 0.190 |
Why?
|
| Multiple Trauma | 1 | 2022 | 27 | 0.190 |
Why?
|
| Surgical Wound Infection | 2 | 2020 | 117 | 0.190 |
Why?
|
| Wound Infection | 1 | 2022 | 28 | 0.180 |
Why?
|
| Genetic Markers | 1 | 2021 | 130 | 0.180 |
Why?
|
| Tissue Array Analysis | 2 | 2019 | 37 | 0.180 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2021 | 27 | 0.170 |
Why?
|
| Intermittent Urethral Catheterization | 1 | 2021 | 1 | 0.170 |
Why?
|
| Antimicrobial Stewardship | 1 | 2020 | 16 | 0.170 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2020 | 16 | 0.170 |
Why?
|
| Phenotype | 1 | 2024 | 1207 | 0.160 |
Why?
|
| Debridement | 1 | 2019 | 33 | 0.160 |
Why?
|
| Risk Adjustment | 1 | 2020 | 94 | 0.160 |
Why?
|
| Colon | 1 | 2021 | 149 | 0.160 |
Why?
|
| Feasibility Studies | 2 | 2025 | 571 | 0.150 |
Why?
|
| Male Urogenital Diseases | 1 | 2018 | 4 | 0.140 |
Why?
|
| Adolescent | 5 | 2020 | 6260 | 0.140 |
Why?
|
| Autografts | 1 | 2018 | 9 | 0.140 |
Why?
|
| Fracture Fixation, Internal | 1 | 2018 | 65 | 0.140 |
Why?
|
| Biopsy | 1 | 2019 | 446 | 0.140 |
Why?
|
| Prognosis | 3 | 2019 | 1744 | 0.140 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2008 | 43 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 3 | 2014 | 280 | 0.140 |
Why?
|
| Salvage Therapy | 1 | 2017 | 75 | 0.130 |
Why?
|
| United States | 7 | 2024 | 7849 | 0.130 |
Why?
|
| Injections, Intralesional | 2 | 2020 | 14 | 0.130 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2008 | 105 | 0.130 |
Why?
|
| Urination Disorders | 1 | 2016 | 8 | 0.130 |
Why?
|
| Protein Biosynthesis | 1 | 2019 | 320 | 0.130 |
Why?
|
| Urogenital Surgical Procedures | 1 | 2016 | 5 | 0.130 |
Why?
|
| Lymphedema | 1 | 2016 | 7 | 0.130 |
Why?
|
| Tissue Engineering | 1 | 2018 | 141 | 0.130 |
Why?
|
| Injury Severity Score | 2 | 2018 | 109 | 0.130 |
Why?
|
| Internship and Residency | 1 | 2024 | 809 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 723 | 0.120 |
Why?
|
| Rheology | 1 | 2016 | 74 | 0.120 |
Why?
|
| Infant | 1 | 2020 | 1654 | 0.120 |
Why?
|
| Child, Preschool | 1 | 2020 | 1999 | 0.110 |
Why?
|
| Biomarkers, Tumor | 2 | 2008 | 507 | 0.110 |
Why?
|
| Anxiety | 1 | 2018 | 429 | 0.110 |
Why?
|
| Reproducibility of Results | 3 | 2025 | 1666 | 0.110 |
Why?
|
| Recovery of Function | 3 | 2019 | 287 | 0.090 |
Why?
|
| Poisson Distribution | 1 | 2012 | 53 | 0.090 |
Why?
|
| Abdominal Injuries | 1 | 2012 | 33 | 0.090 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2012 | 113 | 0.090 |
Why?
|
| Lymphatic Metastasis | 2 | 2008 | 92 | 0.090 |
Why?
|
| Depression | 1 | 2018 | 908 | 0.080 |
Why?
|
| Child | 1 | 2020 | 4541 | 0.080 |
Why?
|
| Intraoperative Complications | 1 | 2010 | 92 | 0.080 |
Why?
|
| Psychometrics | 2 | 2025 | 384 | 0.080 |
Why?
|
| Health Care Costs | 1 | 2010 | 215 | 0.070 |
Why?
|
| Cadherins | 1 | 2008 | 80 | 0.070 |
Why?
|
| Societies, Medical | 2 | 2024 | 379 | 0.070 |
Why?
|
| Acute Disease | 1 | 2009 | 671 | 0.070 |
Why?
|
| Silver | 1 | 2007 | 15 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 1 | 2007 | 92 | 0.070 |
Why?
|
| Hospital Mortality | 1 | 2012 | 873 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 731 | 0.070 |
Why?
|
| Surgical Mesh | 1 | 2007 | 58 | 0.070 |
Why?
|
| Prosthesis-Related Infections | 1 | 2007 | 34 | 0.070 |
Why?
|
| Critical Care | 1 | 2010 | 397 | 0.070 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2007 | 45 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 2007 | 220 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 791 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2019 | 851 | 0.060 |
Why?
|
| Age Factors | 2 | 2021 | 1565 | 0.060 |
Why?
|
| Printing, Three-Dimensional | 1 | 2025 | 38 | 0.060 |
Why?
|
| Delphi Technique | 1 | 2025 | 101 | 0.060 |
Why?
|
| Metal Nanoparticles | 1 | 2007 | 186 | 0.050 |
Why?
|
| Consensus | 1 | 2025 | 201 | 0.050 |
Why?
|
| Personnel Selection | 1 | 2024 | 56 | 0.050 |
Why?
|
| Prevalence | 2 | 2018 | 1387 | 0.050 |
Why?
|
| Abdomen | 1 | 2023 | 92 | 0.050 |
Why?
|
| Fascia | 1 | 2022 | 5 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 784 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2023 | 267 | 0.050 |
Why?
|
| Obesity | 2 | 2022 | 1235 | 0.040 |
Why?
|
| Nitrofurantoin | 1 | 2020 | 10 | 0.040 |
Why?
|
| History, 19th Century | 1 | 2021 | 42 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 1259 | 0.040 |
Why?
|
| Cryosurgery | 1 | 2020 | 28 | 0.040 |
Why?
|
| Catheters, Indwelling | 1 | 2020 | 69 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2020 | 68 | 0.040 |
Why?
|
| Perioperative Care | 1 | 2020 | 85 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2021 | 172 | 0.040 |
Why?
|
| Observer Variation | 1 | 2020 | 215 | 0.040 |
Why?
|
| Weight Loss | 1 | 2022 | 274 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2021 | 230 | 0.040 |
Why?
|
| Device Removal | 1 | 2020 | 68 | 0.040 |
Why?
|
| Abbreviated Injury Scale | 1 | 2018 | 10 | 0.040 |
Why?
|
| Urinary Catheters | 1 | 2018 | 5 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2019 | 240 | 0.040 |
Why?
|
| Genitalia, Male | 1 | 2018 | 10 | 0.040 |
Why?
|
| Pathologists | 1 | 2018 | 14 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2018 | 215 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 138 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2018 | 137 | 0.030 |
Why?
|
| Risk | 1 | 2018 | 378 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 1093 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2018 | 286 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 421 | 0.030 |
Why?
|
| Organ Sparing Treatments | 1 | 2016 | 16 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2008 | 585 | 0.030 |
Why?
|
| Electrocoagulation | 1 | 2016 | 13 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2016 | 55 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2016 | 65 | 0.030 |
Why?
|
| California | 1 | 2016 | 174 | 0.030 |
Why?
|
| Symptom Assessment | 1 | 2016 | 47 | 0.030 |
Why?
|
| Operative Time | 1 | 2016 | 92 | 0.030 |
Why?
|
| Skin Transplantation | 1 | 2016 | 154 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 1117 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2016 | 208 | 0.030 |
Why?
|
| Vagina | 1 | 2014 | 83 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 606 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2018 | 727 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 1152 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 709 | 0.020 |
Why?
|
| Registries | 1 | 2016 | 879 | 0.020 |
Why?
|
| Hospitalization | 1 | 2018 | 1361 | 0.020 |
Why?
|
| Radiography | 1 | 2012 | 551 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 2586 | 0.020 |
Why?
|
| Catenins | 1 | 2007 | 14 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2007 | 64 | 0.020 |
Why?
|
| Methicillin Resistance | 1 | 2007 | 23 | 0.020 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2007 | 30 | 0.020 |
Why?
|
| Materials Testing | 1 | 2007 | 86 | 0.020 |
Why?
|
| Transfection | 1 | 2008 | 694 | 0.020 |
Why?
|
| Cell Movement | 1 | 2008 | 456 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2007 | 205 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2007 | 224 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2007 | 612 | 0.020 |
Why?
|
| Staphylococcus aureus | 1 | 2007 | 176 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2007 | 518 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2007 | 921 | 0.010 |
Why?
|